WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...

WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing ...

WuXi Biologics’ subsidiary WuXi Vaccines is divesting a manufacturing facility in Dundalk, Ireland, to Merck for $500 million ...

Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a ...

In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...

MSD acquires WuXi Vaccines' Dundalk facility with a €500 million investment, creating 1,000 new jobs across Ireland and ...

BALTIMORE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals, a pioneer in non-degrading molecular glue therapeutics, announced today that it will host an executive roundtable at the WuXi ...

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...

WUXI Biologics Cayman will sell a vaccine facility in Ireland to Merck for about US$500 million as the Chinese company seeks ...

WuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland ...